JP2015189684A - Soft capsule coating and soft capsule - Google Patents
Soft capsule coating and soft capsule Download PDFInfo
- Publication number
- JP2015189684A JP2015189684A JP2014066728A JP2014066728A JP2015189684A JP 2015189684 A JP2015189684 A JP 2015189684A JP 2014066728 A JP2014066728 A JP 2014066728A JP 2014066728 A JP2014066728 A JP 2014066728A JP 2015189684 A JP2015189684 A JP 2015189684A
- Authority
- JP
- Japan
- Prior art keywords
- soft capsule
- weight
- parts
- film
- capsule film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007901 soft capsule Substances 0.000 title claims abstract description 98
- 238000000576 coating method Methods 0.000 title abstract description 32
- 239000011248 coating agent Substances 0.000 title abstract description 29
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000000679 carrageenan Substances 0.000 claims abstract description 39
- 229920001525 carrageenan Polymers 0.000 claims abstract description 39
- 229940113118 carrageenan Drugs 0.000 claims abstract description 39
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000000176 sodium gluconate Substances 0.000 claims abstract description 26
- 235000012207 sodium gluconate Nutrition 0.000 claims abstract description 26
- 229940005574 sodium gluconate Drugs 0.000 claims abstract description 26
- 108010010803 Gelatin Proteins 0.000 claims abstract description 18
- 239000008273 gelatin Substances 0.000 claims abstract description 18
- 229920000159 gelatin Polymers 0.000 claims abstract description 18
- 235000019322 gelatine Nutrition 0.000 claims abstract description 18
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims abstract description 11
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 claims abstract description 11
- 229940050410 gluconate Drugs 0.000 claims abstract description 11
- 239000004224 potassium gluconate Substances 0.000 claims abstract description 11
- 235000013926 potassium gluconate Nutrition 0.000 claims abstract description 11
- 229960003189 potassium gluconate Drugs 0.000 claims abstract description 11
- 229920002261 Corn starch Polymers 0.000 claims abstract description 10
- 239000008120 corn starch Substances 0.000 claims abstract description 10
- 235000010418 carrageenan Nutrition 0.000 claims description 38
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 38
- 230000032050 esterification Effects 0.000 claims description 11
- 238000005886 esterification reaction Methods 0.000 claims description 11
- 230000009435 amidation Effects 0.000 claims description 8
- 238000007112 amidation reaction Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 abstract description 3
- 229920002472 Starch Polymers 0.000 description 46
- 235000019698 starch Nutrition 0.000 description 45
- 239000008107 starch Substances 0.000 description 44
- 230000000704 physical effect Effects 0.000 description 29
- 239000007788 liquid Substances 0.000 description 25
- 239000000203 mixture Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 5
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 239000001814 pectin Substances 0.000 description 5
- 235000010987 pectin Nutrition 0.000 description 5
- 229920001277 pectin Polymers 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 108010025899 gelatin film Proteins 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015870 tripotassium citrate Nutrition 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
本発明は、ゼラチンを使用しない腸溶性のソフトカプセル皮膜、及び、該ソフトカプセル皮膜を備えるソフトカプセルに関するものである。 The present invention relates to an enteric soft capsule film that does not use gelatin and a soft capsule including the soft capsule film.
ソフトカプセルの皮膜基剤として一般的に用いられているゼラチンは、温度変化により可逆的にゾル・ゲル変化すること、皮膜形成能に優れると共に形成された皮膜の機械的強度が高いこと、体内で崩壊又は溶解しやすいこと、それ自体が栄養的価値を有し体内に吸収され易いこと等、皮膜基剤としての利点を多く有している。 Gelatin, which is generally used as a film base for soft capsules, reversibly changes to sol and gel with changes in temperature, has excellent film-forming ability and high mechanical strength, and disintegrates in the body. Alternatively, it has many advantages as a film base, such as being easily dissolved and having itself nutritional value and being easily absorbed into the body.
一方、ソフトカプセルには、胃酸によって効能を失う成分や、胃の組織に刺激を与える成分等を内容物としたい場合があり、そのような場合、ソフトカプセル皮膜には、胃では崩壊又は溶解せずに腸に到達してから崩壊又は溶解する性質(腸溶性)を有することが要請される。しかしながら、ゼラチンは強酸性の胃液に容易に溶解してしまい、腸溶性を有していない。 On the other hand, soft capsules may want to contain components that lose their efficacy due to stomach acid or components that irritate stomach tissue. In such cases, soft capsules do not disintegrate or dissolve in the stomach. It is required to have the property of disintegrating or dissolving (enteric) after reaching the intestine. However, gelatin is easily dissolved in strongly acidic gastric juice and is not enteric.
そこで、従来、成形されたゼラチン皮膜の外表面にツェインやセラック等の腸溶性物質をコーティングする技術、または、多価金属イオンによりゲル化して耐胃液性を示す多糖類を、ゼラチンを主成分とするソフトカプセル皮膜に含有させておき、成形されたソフトカプセル皮膜を多価イオンを含有する水溶液に浸漬することによって耐胃液性の外皮を形成させる技術(例えば、特許文献1参照)、或いは、多価金属イオンの非水溶性塩(難水溶性塩)を予めソフトカプセル皮膜に含有させておき、胃酸中で多価金属イオンを解離させて多糖類にゲル化反応を起こさせて耐胃液性の外皮を形成させる技術(例えば、特許文献2参照)が提案されている。また、本出願人は、エステル化度が所定範囲の低メトキシルペクチンを、ゼラチンに対して所定量含有させることで、ゼラチン皮膜に腸溶性を付与する技術を提案している(特許技術3参照)。 Therefore, conventionally, a technique for coating the outer surface of a formed gelatin film with an enteric substance such as zein or shellac, or a polysaccharide gelled with polyvalent metal ions and exhibiting gastric juice resistance, and gelatin as a main component. A technique for forming a gastric juice-resistant skin by immersing the formed soft capsule film in an aqueous solution containing polyvalent ions (for example, see Patent Document 1), or a polyvalent metal A water-insoluble salt of ion (slightly water-soluble salt) is previously contained in the soft capsule film, and the polyvalent metal ion is dissociated in gastric acid to cause a gelation reaction on the polysaccharide to form a gastric juice-resistant skin. The technique (for example, refer patent document 2) to be made is proposed. Further, the present applicant has proposed a technique for imparting enteric properties to a gelatin film by containing a predetermined amount of low methoxyl pectin having a degree of esterification in a predetermined range with respect to gelatin (see Patent Technology 3). .
しかしながら、ゼラチンは牛や豚などの動物の皮、骨、腱などを処理して得られる誘導タンパク質の一種であるため、狂牛病(牛海綿状脳症)対策や宗教上の理由などにより敬遠される傾向がある。そのため、上記の従来の腸溶性ソフトカプセル皮膜とは異なり、ゼラチンを使用していない腸溶性のソフトカプセル皮膜、及び、このようなソフトカプセル皮膜を備えるソフトカプセルが、要請されていた。 However, since gelatin is a type of derived protein obtained by processing the skin, bones, tendons, etc. of animals such as cattle and pigs, it is shunned for measures such as mad cow disease (bovine spongiform encephalopathy) and religious reasons. There is a tendency to. Therefore, unlike the above-mentioned conventional enteric soft capsule film, an enteric soft capsule film not using gelatin and a soft capsule provided with such a soft capsule film have been demanded.
そこで、本発明は、上記の実情に鑑み、ゼラチンを含有しないと共に腸溶性を備えているソフトカプセル皮膜、及び、該ソフトカプセル皮膜を備えるソフトカプセルの提供を、課題とするものである。 Then, this invention makes it a subject to provide the soft capsule film | membrane which does not contain gelatin and is enteric, and a soft capsule provided with this soft capsule film | membrane in view of said situation.
上記の課題を解決するため、本発明にかかるソフトカプセル皮膜は、「塩の存在下で湿式加熱処理されたもち種トウモロコシ澱粉と、グルコン酸ナトリウム及びグルコン酸カリウムの何れかであるグルコン酸塩と、低メトキシルペクチンと、イオタカラギーナンとを含有し、ゼラチンを含有しない」ものである。 In order to solve the above-described problems, the soft capsule film according to the present invention includes: a glutinous corn starch that has been wet-heat treated in the presence of a salt, a gluconate that is one of sodium gluconate and potassium gluconate, It contains methoxyl pectin and iota carrageenan and no gelatin ".
「塩の存在下での湿式加熱処理」は、加熱しても糊化しない程度の水分の存在下で、塩と澱粉の混合物を温度100〜150℃に加熱する処理を指しており、「塩」としてはナトリウム、カリウム、マグネシウム、カルシウムの塩化物を例示することができる。なお、以下において、「塩の存在下で湿式加熱処理されたもち種トウモロコシ澱粉」を、「湿式加熱処理澱粉」と称する場合がある。 “Wet heat treatment in the presence of salt” refers to a treatment in which a mixture of salt and starch is heated to a temperature of 100 to 150 ° C. in the presence of moisture that does not gelatinize even when heated. "Can be exemplified by chlorides of sodium, potassium, magnesium and calcium. In the following, “glutinous corn starch that has been wet-heat treated in the presence of salt” may be referred to as “wet heat-treated starch”.
「低メトキシルペクチン」は、ガラクチュロン酸とそのメチルエステルが重合した多糖類であるペクチンのうち、エステル化度が50%より低いペクチンである。ここで、「エステル化度(DE:Degree of Esterifiation)」とは、全ガラクチュロン酸のうちメチルエステルの形で存在するガラクチュロン酸の割合である。なお、エステル化度が50%以上のペクチンは「高メトキシルペクチン」と称されている。 “Low methoxyl pectin” is a pectin having a degree of esterification lower than 50% among pectin, which is a polysaccharide obtained by polymerizing galacturonic acid and its methyl ester. Here, the “degree of esterification (DE)” is the ratio of galacturonic acid existing in the form of methyl ester out of all galacturonic acid. A pectin having an esterification degree of 50% or more is referred to as “high methoxyl pectin”.
本発明者らは、湿式加熱処理澱粉、イオタカラギーナン、及び、低メトキシルペクチンを含有させたソフトカプセル皮膜について、組成等を異ならせて種々検討したものの、ソフトカプセル皮膜として適した物性を有すると共に腸溶性を有するソフトカプセル皮膜は、得られなかった。そこで、更に検討を進めた結果、グルコン酸ナトリウム及びグルコン酸カリウムの何れかを含有させることにより、ソフトカプセル皮膜として適した物性を有すると共に腸溶性を有するソフトカプセル皮膜を得られることを見出し、本発明に至ったものである。従って、本発明によれば、ゼラチンを含有しないと共に腸溶性を備えたソフトカプセル皮膜を、提供することができる。 The inventors of the present invention have studied various types of soft capsule films containing wet heat-treated starch, iota carrageenan and low methoxyl pectin with different compositions, etc., but have physical properties suitable as soft capsule films and enteric properties. No soft capsule film was obtained. Therefore, as a result of further investigation, it was found that by containing either sodium gluconate or potassium gluconate, a soft capsule film having physical properties suitable as a soft capsule film and having enteric properties can be obtained. It has come. Therefore, according to the present invention, a soft capsule film which does not contain gelatin and has enteric properties can be provided.
また、本発明のソフトカプセル皮膜は、上記の従来技術とは異なり、腸溶性を付与するためのコーティング工程や浸漬工程は不要であり、極めて簡易に製造することができる。 Further, unlike the above-described conventional technique, the soft capsule film of the present invention does not require a coating process or an immersion process for imparting enteric properties, and can be manufactured very easily.
本発明にかかるソフトカプセル皮膜は、上記構成に加え、「低メトキシルペクチンはエステル化度が26%〜27%であり、且つ、アミド化度が20%〜22%である」もの、「塩の存在下で湿式加熱処理されたもち種トウモロコシ澱粉100重量部に対して5重量部〜5.5重量部の前記グルコン酸塩を含有している」もの、「塩の存在下で湿式加熱処理されたもち種トウモロコシ澱粉100重量部に対して40重量部〜45重量部のイオタカラギーナンを含有している」もの、或いは、「イオタカラギーナンに対する質量比が2:1〜1.8:1の前記低メトキシルペクチンを含有している」ものとすることができる。 In addition to the above structure, the soft capsule film according to the present invention has a “low methoxyl pectin having an esterification degree of 26% to 27% and an amidation degree of 20% to 22%”, “the presence of salt Potato seeds containing 5 parts by weight to 5.5 parts by weight of the gluconate based on 100 parts by weight of glutinous corn starch that has been wet-heat treated under the conditions of "a glutinous seed that has been wet-heat-treated in the presence of salt" Containing 40 to 45 parts by weight of iota carrageenan per 100 parts by weight of corn starch, or “low methoxyl pectin having a mass ratio of 2: 1 to 1.8: 1 with respect to iota carrageenan It can be included ".
ペクチンの「アミド化度(DA:Degree of Amidation)」は、全ガラクチュロン酸のうちアミド基を有するガラクチュロン酸の割合である。 The “degree of amidation (DA)” of pectin is the ratio of galacturonic acid having an amide group to the total galacturonic acid.
上記組成とすることにより、後述のように、ソフトカプセル皮膜としてより適した物性と腸溶性に優れるソフトカプセル皮膜を得ることができる。 By setting it as the said composition, the soft capsule membrane | film | coat which is more suitable as a soft capsule membrane | film | coat and is excellent in the enteric property as mentioned later can be obtained.
次に、本発明にかかるソフトカプセルは、「上記に記載のソフトカプセル皮膜に内容物が充填されたソフトカプセル」である。 Next, the soft capsule according to the present invention is “a soft capsule in which the content of the soft capsule film described above is filled”.
「内容物」としては、医薬成分、健康食品成分、栄養補助成分などの目的物質を、油脂または油状物質に溶解または懸濁させたもの、或いは、上記の目的物質自体が油状やペースト状であるものを使用することができる。また、特に限定されるものではないが、乳酸菌など胃酸によって活性を失いやすい成分や、鉄分など胃の細胞壁に刺激を与えやすい成分は、本発明のソフトカプセルの内容物とする意義が高い。 “Contents” include a substance obtained by dissolving or suspending a target substance such as a pharmaceutical ingredient, health food ingredient or nutritional supplement in an oil or oily substance, or the target substance itself is oily or pasty. Things can be used. Further, although not particularly limited, components that easily lose their activity due to stomach acid, such as lactic acid bacteria, and components that easily cause irritation to the cell wall of the stomach, such as iron, are highly significant as the contents of the soft capsule of the present invention.
本構成により、ソフトカプセル皮膜にゼラチンを含有しないことにより需要者に受け容れられやすいソフトカプセルであり、且つ、腸溶性に優れたソフトカプセルを、提供することができる。 According to this configuration, it is possible to provide a soft capsule that is easily accepted by a customer by not containing gelatin in the soft capsule film and that is excellent in enteric properties.
以上のように、本発明の効果として、ゼラチンを含有しないと共に腸溶性を備えたソフトカプセル皮膜、及び、該ソフトカプセル皮膜を備えるソフトカプセルを、提供することができる。 As described above, as an effect of the present invention, it is possible to provide a soft capsule film that does not contain gelatin and has enteric properties, and a soft capsule that includes the soft capsule film.
以下、本発明の一実施形態であるソフトカプセル皮膜、及び、該ソフトカプセル皮膜を備えるソフトカプセルについて説明する。 Hereinafter, a soft capsule film that is an embodiment of the present invention and a soft capsule including the soft capsule film will be described.
本実施形態のソフトカプセル皮膜は、塩の存在下で湿式加熱処理されたもち種トウモロコシ澱粉と、グルコン酸ナトリウム及びグルコン酸カリウムの何れかであるグルコン酸塩と、低メトキシルペクチンと、イオタカラギーナンとを含有し、ゼラチンを含有しないものである。 The soft capsule film of the present embodiment contains glutinous corn starch that has been wet-heat treated in the presence of salt, gluconate that is either sodium gluconate or potassium gluconate, low methoxyl pectin, and iota carrageenan. However, it does not contain gelatin.
また、塩の存在下で湿式加熱処理されたもち種トウモロコシ澱粉100重量部に対して、5.0重量部〜5.5重量部のグルコン酸ナトリウム、40重量部〜45重量部のイオタカラギーナン、及び、イオタカラギーナンに対する質量比が2:1〜1.8:1の低メトキシルペクチンを含有している。また、低メトキシルペクチンはエステル化度が26%〜27%であり、且つ、アミド化度が20%〜22%である。 Also, 5.0 parts by weight to 5.5 parts by weight of sodium gluconate, 40 parts by weight to 45 parts by weight of iota carrageenan, and 100 parts by weight of glutinous corn starch that has been wet-heat treated in the presence of salt, and And low methoxyl pectin having a mass ratio of 2: 1 to 1.8: 1 with respect to iota carrageenan. Low methoxyl pectin has an esterification degree of 26% to 27% and an amidation degree of 20% to 22%.
本実施形態のソフトカプセル皮膜を、上記組成とした根拠について説明する。まず、表1に組成を示すように、湿式加熱処理澱粉100重量部に対して、5.0重量部のグルコン酸ナトリウム、40重量部のイオタカラギーナン、20重量部の低メトキシルペクチン(LMペクチン)、グリセリン、及び水から皮膜液を調製し、表2に示すように、低メトキシルペクチンとしてエステル化度(%)及びアミド化度(%)の異なる種類を使用した試料P1〜試料P11について、以下の方法で皮膜の物性と腸溶性を評価した。なお、湿式加熱処理澱粉としては、三和澱粉工業株式会社製、ソフトスターチSF−930を使用した。 The reason why the soft capsule film of the present embodiment has the above composition will be described. First, as shown in Table 1, 5.0 parts by weight of sodium gluconate, 40 parts by weight of iota carrageenan, 20 parts by weight of low methoxyl pectin (LM pectin) per 100 parts by weight of wet heat-treated starch Samples P1 to P11 using different types of esterification degree (%) and amidation degree (%) as low methoxyl pectin as shown in Table 2 were prepared from glycerin and water. The physical properties and enteric properties of the film were evaluated by the above method. In addition, as a wet heat-processed starch, the Sanwa Starch Co., Ltd. make and soft starch SF-930 were used.
<皮膜の物性の評価>
ロータリーダイ式でソフトカプセルを成形することを想定して、皮膜液をガラス板に流延した後、乾燥させてゲル化した皮膜を常温で剥がす試験を行った。皮膜が切れない、皮膜が脆くなく適度な柔軟性を有する、皮膜が粘着せずガラス板から剥がれ易い場合を、「ソフトカプセル皮膜として適した物性」を有すると評価して「○」で表示し、そうでない場合を不適であると評価して「×」で表示した。評価結果を表2に示す。
<Evaluation of physical properties of film>
Assuming that a soft capsule is formed by a rotary die method, a test was performed in which a coating solution was cast on a glass plate, and then the dried and gelled coating was peeled off at room temperature. When the film is not cut, the film is not brittle and has appropriate flexibility, and the film is not sticky and easily peeled off from the glass plate, it is evaluated as having `` physical properties suitable as a soft capsule film '' and indicated with `` ○ '' The case where it was not so was evaluated as unsuitable, and displayed as “×”. The evaluation results are shown in Table 2.
<腸溶性の評価>
日本薬局方に規定された崩壊試験法に則り、第一液及び第二液を使用して行った。ここで、第一液は耐胃液性を評価するためのpH1.2の試験液であり、試験液中でソフトカプセル皮膜を所定時間上下運動させ、その後の観察においてソフトカプセル皮膜が残存しているか否かを確認した。また、第二液は耐腸液性を評価するためのpH6.8の試験液であり、試験液中でソフトカプセル皮膜を所定時間上下運動させ、その後の観察において、ソフトカプセル皮膜が残存しているか否かを確認した。評価は、ソフトカプセル皮膜が、第一液による崩壊試験において残存し、第二液による崩壊試験において崩壊する場合に腸溶性を有するものとして「○」で表示し、それ以外の場合、つまり第一液による崩壊試験において崩壊する場合、及び、第一液による崩壊試験において残存するが、第二液による崩壊試験においても残存する場合は「×」と表示した。なお、第一液による崩壊試験において崩壊する場合は、第二液による試験は行わなかった。
<Evaluation of enteric properties>
According to the disintegration test method prescribed in the Japanese Pharmacopoeia, the first and second liquids were used. Here, the first solution is a pH 1.2 test solution for evaluating gastric juice resistance, and the soft capsule film is moved up and down for a predetermined time in the test solution, and whether or not the soft capsule film remains in the subsequent observation. It was confirmed. The second liquid is a test liquid having a pH of 6.8 for evaluating the resistance to intestinal juice. The soft capsule film is moved up and down for a predetermined time in the test liquid, and whether or not the soft capsule film remains in the subsequent observation. It was confirmed. In the evaluation, when the soft capsule film remains in the disintegration test with the first liquid and disintegrates in the disintegration test with the second liquid, it is indicated with “O” as having enteric properties, and in other cases, that is, the first liquid In the case of disintegration in the disintegration test by and the remaining in the disintegration test by the first liquid, but also in the disintegration test by the second liquid, “x” was indicated. In addition, when disintegrating in the disintegration test using the first liquid, the test using the second liquid was not performed.
上述したように、グルコン酸塩を含有しない皮膜液からはソフトカプセル皮膜として適した物性を有すると共に腸溶性を有する皮膜が得られなかったところ、グルコン酸ナトリウムを混合させた場合、試料P1〜P5及び試料P10の皮膜は、ソフトカプセル皮膜として適した物性を有しており、そのうち試料P1,P2,P10は腸溶性を有していた。 As described above, when a coating solution not containing gluconate has physical properties suitable as a soft capsule coating and an enteric coating is not obtained, when sodium gluconate is mixed, samples P1 to P5 and The film of Sample P10 had physical properties suitable as a soft capsule film, and Samples P1, P2, and P10 had enteric properties.
試料P1〜P11に用いた低メトキシルペクチンのエステル化度とアミド化度から、上記の組成において、低メトキシルペクチンのエステル化度が26%〜27%で、且つ、アミド化度20%〜22%である場合に、ソフトカプセル皮膜として適した物性を有すると共に腸溶性を有するソフトカプセル皮膜が得られると考えられた。 From the esterification degree and amidation degree of the low methoxyl pectin used for the samples P1 to P11, in the above composition, the esterification degree of the low methoxyl pectin is 26% to 27% and the amidation degree is 20% to 22%. In this case, it was considered that a soft capsule film having physical properties suitable as a soft capsule film and having enteric properties was obtained.
ここで、表2に示した結果は、表1の組成においてグルコン酸ナトリウムに代替してグルコン酸カリウムを用いた場合においても同じ結果であった。グルコン酸ナトリウム、グルコン酸カリウムは共に、pH調整剤として使用されることが多い。そこで、同じくpH調整剤として使用されるグルコン酸銅、グルコン酸亜鉛、グルコン酸カルシウム、クエン酸三ナトリウム、クエン酸三カリウム、リン酸水素二ナトリウム、ピロリン酸ナトリウムについて、表1においてグルコン酸ナトリウムに代替した組成で、表2と同様に低メトキシルペクチンの種類を異ならせて皮膜を成形したが、ソフトカプセル皮膜として適した物性と腸溶性とを共に有する皮膜を得ることはできなかった。 Here, the results shown in Table 2 were the same results when potassium gluconate was used instead of sodium gluconate in the composition of Table 1. Both sodium gluconate and potassium gluconate are often used as pH adjusters. Therefore, copper gluconate, zinc gluconate, calcium gluconate, trisodium citrate, tripotassium citrate, disodium hydrogen phosphate and sodium pyrophosphate, which are also used as pH adjusters, are listed in Table 1 as sodium gluconate. In the alternative composition, the film was formed by changing the kind of low methoxyl pectin as in Table 2. However, it was not possible to obtain a film having both physical properties and enteric properties suitable as a soft capsule film.
また、グルコン酸ナトリウム及びグルコン酸カリウムをそれぞれ使用した表1の組成では、皮膜液のpHは5.2〜5.3であったため、上記の他のpH調整剤を混合した皮膜液のpHが同程度の値となるように、pH調整剤の添加量を調整した場合について、試料P1の低メトキシルペクチンを使用して皮膜を成形した。しかしながら、これらの場合も、ソフトカプセル皮膜として適した物性と腸溶性とを共に有する皮膜を得ることはできなかった。従って、グルコン酸塩の添加によってソフトカプセル皮膜として適した物性と腸溶性とを共に有する皮膜が形成される効果は、pH調整剤によるpH調整によるものではなく、グルコン酸ナトリウム及びグルコン酸カリウムに特異的な作用によると考えられた。 Moreover, in the composition of Table 1 using each of sodium gluconate and potassium gluconate, the pH of the coating solution was 5.2 to 5.3. Therefore, the pH of the coating solution mixed with the above other pH adjusters was A film was formed using the low methoxyl pectin of sample P1 in the case where the addition amount of the pH adjusting agent was adjusted so as to have a comparable value. However, even in these cases, it was impossible to obtain a film having both physical properties and enteric properties suitable as a soft capsule film. Therefore, the effect of forming a film having both physical properties and enteric properties suitable as a soft capsule film by the addition of gluconate is not due to pH adjustment by a pH adjuster, but is specific to sodium gluconate and potassium gluconate. It was thought that it was due to the effect.
次に、湿式加熱処理澱粉の配合量について検討した結果を示す。試料P1の低メトキシルペクチンを使用し、表1の組成において湿式加熱処理澱粉の配合量を増加させ、その分だけ水を減量した組成の試料S1〜S3について、皮膜液から皮膜を成形し、上記と同様に皮膜の物性と腸溶性を評価した。その結果を、表3に示す。 Next, the result of having examined about the compounding quantity of wet heat processing starch is shown. Using the low methoxyl pectin of sample P1, increasing the blending amount of the wet heat-treated starch in the composition of Table 1, forming a film from the film solution for samples S1 to S3 having a composition in which the amount of water was reduced, The physical properties and enteric properties of the film were evaluated in the same manner. The results are shown in Table 3.
表3に示すように、湿式加熱処理澱粉の配合量が、皮膜液の全量の20質量%を超える試料S2,S3では、ソフトカプセル皮膜として適した物性の皮膜を形成できるものの、腸溶性を有さないものであった。また、試料S2,S3の皮膜液は分散性が低く、皮膜の均一性も低いものであった。従って、湿式加熱処理澱粉の配合量は、皮膜液の全量の20質量%以下とするのが望ましく、配合できる最大量として20質量%とするのがより望ましい。ここで、皮膜液の全量の20質量%の湿式加熱処理澱粉は、表1の組成の皮膜液から製造されたソフトカプセル皮膜における湿式加熱処理澱粉、グルコン酸塩(グルコン酸ナトリウム又はグルコン酸カリウム)、イオタカラギーナン、及び低メトキシルペクチンの質量の総和に対し、61質量%に相当する。また、ソフトカプセル皮膜の水分含有率を6〜7質量%とすると、皮膜液の全量の20質量%の湿式加熱処理澱粉は、表1の組成の皮膜液から製造されたソフトカプセル皮膜においては38質量%に相当する。 As shown in Table 3, the samples S2 and S3 in which the amount of the wet heat-treated starch exceeds 20% by mass of the total amount of the coating liquid can form a film having physical properties suitable as a soft capsule film, but has enteric properties. It was not. Further, the coating liquids of Samples S2 and S3 had low dispersibility and low film uniformity. Therefore, the blending amount of the wet heat-treated starch is desirably 20% by mass or less of the total amount of the coating liquid, and more desirably 20% by mass as the maximum amount that can be blended. Here, 20 mass% wet heat-treated starch of the total amount of the coating liquid is a wet heat-treated starch, gluconate (sodium gluconate or potassium gluconate) in a soft capsule film produced from the coating liquid having the composition shown in Table 1, This corresponds to 61% by mass with respect to the total mass of iota carrageenan and low methoxyl pectin. Further, when the moisture content of the soft capsule film is 6 to 7% by mass, the wet heat-treated starch of 20% by mass of the total amount of the film liquid is 38% by mass in the soft capsule film produced from the film liquid having the composition shown in Table 1. It corresponds to.
次に、イオタカラギーナンの湿式加熱処理澱粉に対する質量割合について、検討した結果を示す。湿式加熱処理澱粉を皮膜液の全量の20質量%とし、湿式加熱処理澱粉100重量部に対してグルコン酸ナトリウムを5重量部、イオタカラギーナンと試料P1の低メトキシルペクチンとの質量比を2:1として、イオタカラギーナンの割合(湿式加熱処理澱粉100重量部に対する割合)を変化させた試料S11〜S15について、上記と同様の方法で皮膜液を調製し、皮膜の物性の評価及び腸溶性の評価を行った。その結果を表4に示す。 Next, the examination result is shown about the mass ratio with respect to the wet heat processing starch of iota carrageenan. The wet heat-treated starch is 20% by mass of the total amount of the coating liquid, 5 parts by weight of sodium gluconate with respect to 100 parts by weight of the wet heat-treated starch, and the mass ratio of iota carrageenan and low methoxyl pectin of sample P1 is 2: 1. As for samples S11 to S15 in which the ratio of iota carrageenan (ratio to 100 parts by weight of wet heat-treated starch) was changed, a coating solution was prepared in the same manner as described above, and the physical properties and enteric evaluation of the coating were evaluated. went. The results are shown in Table 4.
表4に示すように、試料S13,S14の皮膜は、ソフトカプセル皮膜として適した物性を有していると共に腸溶性を有していた。従って、湿式加熱処理澱粉100重量部に対するイオタカラギーナンの割合を40重量部〜45重量部とすることにより、ソフトカプセル皮膜に適した物性を有し腸溶性に優れたソフトカプセル皮膜が得られると考えられた。なお、イオタカラギーナンの質量割合が40重量部以下であると、皮膜が脆く切れやすく、45重量部以上では皮膜液の均一性が損なわれた。 As shown in Table 4, the films of Samples S13 and S14 had physical properties suitable as a soft capsule film and enteric properties. Therefore, by setting the ratio of iota carrageenan to 100 parts by weight of wet heat-treated starch to 40 parts by weight to 45 parts by weight, it was considered that a soft capsule film having physical properties suitable for a soft capsule film and excellent enteric properties can be obtained. . When the mass ratio of iota carrageenan was 40 parts by weight or less, the film was fragile and easily cut, and when it was 45 parts by weight or more, the uniformity of the coating liquid was impaired.
上記のように求められたイオタカラギーナンの質量割合の望ましい範囲である、湿式加熱処理澱粉100重量部に対する割合40重量部〜45重量部における、低メトキシルペクチンの望ましい質量割合を検討した結果を、次に示す。まず、イオタカラギーナンを上記範囲の下限である40重量部とし、湿式加熱処理澱粉を皮膜液の全量の20質量%、湿式加熱処理澱粉100重量部に対してグルコン酸ナトリウムを5重量部として、試料P1の低メトキシルペクチンの湿式加熱処理澱粉100重量部に対する割合を変化させた試料S21〜S25について、上記と同様の方法で皮膜液を調製し、皮膜の物性の評価及び腸溶性の評価を行った。その結果を表5に示す。 The result of examining the desirable mass ratio of low methoxyl pectin in the ratio of 40 parts by weight to 45 parts by weight with respect to 100 parts by weight of wet heat-treated starch, which is the desirable range of the mass ratio of iota carrageenan determined as described above, Shown in First, 40 parts by weight of iota carrageenan is the lower limit of the above range, 20% by mass of wet-heat-treated starch is 100% by weight of the total amount of the coating solution, and 5 parts by weight of sodium gluconate with respect to 100 parts by weight of wet-heat-treated starch. About sample S21-S25 which changed the ratio with respect to 100 weight part of wet heat-processed starches of the low methoxyl pectin of P1, the coating liquid was prepared by the method similar to the above, and the physical property evaluation and enteric evaluation were performed. . The results are shown in Table 5.
表5に示すように、試料S22,S23の皮膜はソフトカプセル皮膜に適した物性を有していると共に腸溶性を有していた。従って、ソフトカプセル皮膜の組成において、湿式加熱処理澱粉100重量部に対する低メトキシルペクチンの割合を20重量部〜25重量部とすることにより、ソフトカプセル皮膜に適した物性を有し腸溶性に優れたソフトカプセル皮膜が得られると考えられた。これは、イオタカラギーナンと低メトキシルペクチンの質量比としては、2:1〜1.6:1に相当する。 As shown in Table 5, the films of Samples S22 and S23 had physical properties suitable for the soft capsule film and enteric properties. Therefore, in the composition of the soft capsule film, by setting the ratio of low methoxyl pectin to 100 parts by weight of wet heat-treated starch to 20 to 25 parts by weight, the soft capsule film having physical properties suitable for the soft capsule film and excellent enteric properties Was thought to be obtained. This corresponds to a mass ratio of iota carrageenan to low methoxyl pectin of 2: 1 to 1.6: 1.
次に、イオタカラギーナンを上記範囲の上限である45重量部とし、同様に湿式加熱処理澱粉を皮膜液の全量の20質量%、湿式加熱処理澱粉100重量部に対してグルコン酸ナトリウムを5重量部として、試料P1の低メトキシルペクチンの湿式加熱処理澱粉100重量部に対する割合を変化させた試料S31〜S36について、上記と同様の方法で皮膜液を調製し、皮膜の物性の評価及び腸溶性の評価を行った。その結果を表6に示す。 Next, the iota carrageenan is 45 parts by weight which is the upper limit of the above range, and similarly, the wet heat-treated starch is 20% by weight of the total amount of the coating liquid, and 5 parts by weight of sodium gluconate with respect to 100 parts by weight of the wet heat-treated starch. As for samples S31 to S36 in which the ratio of low-methoxyl pectin of sample P1 to 100 parts by weight of wet-heat-treated starch was changed, a coating solution was prepared in the same manner as described above, and the physical properties of the coating and the evaluation of enteric properties were evaluated. Went. The results are shown in Table 6.
表6に示すように、試料S33,S34の皮膜はソフトカプセル皮膜に適した物性を有していると共に腸溶性を有していた。従って、ソフトカプセル皮膜の組成において、湿式加熱処理澱粉100重量部に対する低メトキシルペクチンの割合を22.5重量部〜25重量部とすることにより、ソフトカプセル皮膜に適した物性を有し腸溶性に優れたソフトカプセル皮膜が得られると考えられた。これは、イオタカラギーナンと低メトキシルペクチンの質量比としては、2:1〜1.8:1に相当する。 As shown in Table 6, the films of Samples S33 and S34 had physical properties suitable for the soft capsule film and enteric properties. Therefore, in the composition of the soft capsule film, by setting the ratio of low methoxyl pectin to 100 parts by weight of wet heat-treated starch to 22.5 parts by weight to 25 parts by weight, it has physical properties suitable for the soft capsule film and excellent enteric properties. It was thought that a soft capsule film could be obtained. This corresponds to a mass ratio of iota carrageenan to low methoxyl pectin of 2: 1 to 1.8: 1.
表5及び表6に示した結果を考え合わせると、イオタカラギーナンの質量割合の望ましい範囲(湿式加熱処理澱粉100重量部に対する割合が40重量部〜45重量部)における、低メトキシルペクチンの望ましい質量割合は、イオタカラギーナンに対する質量比として、2:1〜1.8:1であると言うことができる。 Considering the results shown in Table 5 and Table 6 together, the desirable mass ratio of low methoxyl pectin in the desirable range of the mass ratio of iota carrageenan (ratio to 100 parts by weight of wet heat-treated starch is 40 to 45 parts by weight) Can be said to be 2: 1 to 1.8: 1 as a mass ratio to iota carrageenan.
そこで、イオタカラギーナンの質量割合の望ましい範囲(湿式加熱処理澱粉100重量部に対する割合が40重量部〜45重量部)であり、且つ、低メトキシルペクチンの質量割合の望ましい範囲(イオタカラギーナンに対する質量比として2:1〜1.8:1)における、グルコン酸ナトリウムの望ましい質量割合を検討した。まず、イオタカラギーナンが上記範囲の下限(湿式加熱処理澱粉100重量部に対する割合が40重量部)である場合に、低メトキシルペクチンを上記範囲の下限(イオタカラギーナンに対する質量比として2:1)とし、湿式加熱処理澱粉を皮膜液の全量の20質量%として、グルコン酸ナトリウムの湿式加熱処理澱粉100重量部に対する割合を変化させた試料S41〜S49について、上記と同様の方法で皮膜液を調製し、皮膜の物性の評価及び腸溶性の評価を行った。その結果を表7に示す。 Therefore, the desirable range of the mass ratio of iota carrageenan (the ratio of 40 parts by weight to 45 parts by weight with respect to 100 parts by weight of wet heat-treated starch) and the desirable range of the mass ratio of low methoxyl pectin (mass ratio to iota carrageenan) The desirable mass ratio of sodium gluconate in 2: 1 to 1.8: 1) was studied. First, when iota carrageenan is the lower limit of the above range (ratio to 100 parts by weight of wet heat-treated starch is 40 parts by weight), low methoxyl pectin is set to the lower limit of the above range (2: 1 as a mass ratio to iota carrageenan), For the samples S41 to S49 in which the wet heat-treated starch is 20% by mass of the total amount of the film liquid and the ratio of sodium gluconate to 100 parts by weight of the wet heat-treated starch is changed, a film liquid is prepared in the same manner as described above. The physical properties of the film and the enteric properties were evaluated. The results are shown in Table 7.
表7に示すように、試料S42〜S48の皮膜は、ソフトカプセル皮膜に適した物性を有しており、そのうち試料S43,S44は腸溶性を有していた。このことから、ソフトカプセル皮膜の組成において、湿式加熱処理澱粉100重量部に対するグルコン酸ナトリウムの割合を5.0重量部〜5.5重量部とすることにより、ソフトカプセル皮膜に適した物性を有し、腸溶性に優れたソフトカプセル皮膜が得られると考えられた。 As shown in Table 7, the coatings of samples S42 to S48 had physical properties suitable for soft capsule coatings, of which samples S43 and S44 had enteric properties. From this, in the composition of the soft capsule film, by setting the ratio of sodium gluconate to 5.0 parts by weight to 5.5 parts by weight with respect to 100 parts by weight of the wet heat-treated starch, it has physical properties suitable for the soft capsule film, It was thought that a soft capsule film excellent in enteric properties could be obtained.
同様に、湿式加熱処理澱粉を皮膜液の全量の20質量%とし、イオタカラギーナンが上記範囲の下限(湿式加熱処理澱粉100重量部に対する割合が40重量部)であり、且つ、低メトキシルペクチンが上記範囲の上限(イオタカラギーナンに対する質量比として1.8:1)である場合に、グルコン酸ナトリウムの湿式加熱処理澱粉100重量部に対する割合を変化させた試料S51〜S54、イオタカラギーナンが上記範囲の上限(湿式加熱処理澱粉100重量部に対する割合が45重量部)であり、且つ、低メトキシルペクチンが上記範囲の下限(イオタカラギーナンに対する質量比として2:1)である場合に、グルコン酸ナトリウムの湿式加熱処理澱粉100重量部に対する割合を変化させた試料S61〜S64、及び、イオタカラギーナンが上記範囲の上限(湿式加熱処理澱粉100重量部に対する割合が45重量部)であり、且つ、低メトキシルペクチンが上記範囲の上限(イオタカラギーナンに対する質量比として1.8:1)である場合に、グルコン酸ナトリウムの湿式加熱処理澱粉100重量部に対する割合を変化させた試料S71〜S74について、上記と同様の方法で皮膜液を調製し、皮膜の物性の評価及び腸溶性の評価を行った。その結果を、それぞれ表8、表9、及び表10に示す。 Similarly, the wet heat-treated starch is 20 mass% of the total amount of the coating liquid, iota carrageenan is the lower limit of the above range (ratio to 100 parts by weight of wet heat-treated starch is 40 parts by weight), and low methoxyl pectin is the above Samples S51 to S54 in which the ratio of sodium gluconate to 100 parts by weight of the wet heat-treated starch when the upper limit of the range (1.8: 1 as the mass ratio to iota carrageenan) is the upper limit of the above range for iota carrageenan Wet heating of sodium gluconate when the ratio is 45 parts by weight with respect to 100 parts by weight of wet heat-treated starch and low methoxyl pectin is the lower limit of the above range (2: 1 as the mass ratio to iota carrageenan) Samples S61 to S64 in which the ratio with respect to 100 parts by weight of the treated starch was changed, and iota Ginan is the upper limit of the above range (ratio to 100 parts by weight of wet heat-treated starch is 45 parts by weight) and low methoxyl pectin is the upper limit of the above range (1.8: 1 as the mass ratio to iota carrageenan) In addition, with respect to samples S71 to S74 in which the ratio of sodium gluconate to 100 parts by weight of wet-heat-treated starch was changed, a coating solution was prepared in the same manner as described above, and the physical properties of the coating and the enteric evaluation were evaluated. . The results are shown in Table 8, Table 9, and Table 10, respectively.
表8〜表10に示すように、何れの試料の皮膜もソフトカプセル皮膜として適した物性を有しており、そのうち試料S52,S53、S62,S63,S72,S73は腸溶性を有していた。このことから、ソフトカプセル皮膜の組成において、湿式加熱処理澱粉100重量部に対するグルコン酸ナトリウムの割合を5.0重量部〜5.5重量部とすることにより、ソフトカプセル皮膜に適した物性を有し、腸溶性に優れたソフトカプセル皮膜が得られると考えられた。 As shown in Tables 8 to 10, the films of all samples had physical properties suitable as soft capsule films, and among them, samples S52, S53, S62, S63, S72, and S73 had enteric properties. From this, in the composition of the soft capsule film, by setting the ratio of sodium gluconate to 5.0 parts by weight to 5.5 parts by weight with respect to 100 parts by weight of the wet heat-treated starch, it has physical properties suitable for the soft capsule film, It was thought that a soft capsule film excellent in enteric properties could be obtained.
表7〜表10に示した結果を考え合わせると、イオタカラギーナンの質量割合の望ましい範囲(湿式加熱処理澱粉100重量部に対する割合が40重量部〜45重量部)であり、且つ、低メトキシルペクチンの質量割合の望ましい範囲(イオタカラギーナンと低メトキシルペクチンの質量比として、2:1〜1.8:1)における、グルコン酸ナトリウムの望ましい質量割合は、湿式加熱処理澱粉100重量部に対して5.0重量部〜5.5重量部であると言うことができる。 Considering the results shown in Tables 7 to 10, the mass ratio of iota carrageenan is in a desirable range (ratio of 100 parts by weight of wet heat-treated starch is 40 parts by weight to 45 parts by weight), and low methoxyl pectin The desirable mass ratio of sodium gluconate in the desirable mass ratio range (2: 1 to 1.8: 1 as the mass ratio of iota carrageenan and low methoxyl pectin) is 5. It can be said that it is 0 weight part-5.5 weight part.
以上の結果を総合すると、湿式加熱処理澱粉、湿式加熱処理澱粉100重量部に対して、グルコン酸ナトリウム及びグルコン酸カリウムの何れかであるグルコン酸塩を5.0重量部〜5.5重量部、イオタカラギーナンを40重量部〜45重量部、及び、エステル化度が26%〜27%であり、且つ、アミド化度が20%〜22%である低メトキシルペクチンを、イオタカラギーナンに対する質量比で2:1〜1.8:1の割合で含有し、ゼラチンを含有しないソフトカプセル皮膜は、ソフトカプセル皮膜として適した物性を有していると共に腸溶性を有しているということができる。 When the above results are combined, 5.0 parts by weight to 5.5 parts by weight of gluconate, which is either sodium gluconate or potassium gluconate, with respect to 100 parts by weight of wet heat-treated starch and wet heat-treated starch. Low methoxyl pectin having 40 to 45 parts by weight of iota carrageenan and a degree of esterification of 26% to 27% and amidation degree of 20% to 22% in a mass ratio to iota carrageenan. A soft capsule film containing 2: 1 to 1.8: 1 and containing no gelatin has physical properties suitable as a soft capsule film and has enteric properties.
また、このようなソフトカプセル皮膜を備えるソフトカプセルは、上記の組成に基づいて湿式加熱処理澱粉、イオタカラギーナン、低メトキシルペクチン、及び、グルコン酸塩を、可塑剤と共に水に溶解して皮膜液を調製し、例えば、ロータリーダイ式成形装置を用いて、皮膜の成形と同時に内容物を充填することにより、得ることができる。 A soft capsule having such a soft capsule film is prepared by dissolving wet heat-treated starch, iota carrageenan, low methoxyl pectin and gluconate in water together with a plasticizer based on the above composition. For example, it can be obtained by filling the contents simultaneously with the molding of the film using a rotary die molding apparatus.
上記のように、本実施形態によれば、ソフトカプセル皮膜にゼラチンを含有しないことにより需要者に受け容れられやすいソフトカプセルであり、且つ、腸溶性に優れたソフトカプセルを提供することができる。 As described above, according to the present embodiment, it is possible to provide a soft capsule that is easily accepted by consumers by not containing gelatin in the soft capsule film and that has excellent enteric properties.
以上、本発明について好適な実施形態を挙げて説明したが、本発明は上記の実施形態に限定されるものではなく、以下に示すように、本発明の要旨を逸脱しない範囲において、種々の改良及び設計の変更が可能である。 The present invention has been described with reference to the preferred embodiments. However, the present invention is not limited to the above-described embodiments, and various improvements can be made without departing from the scope of the present invention as described below. And design changes are possible.
例えば、可塑剤としてグリセリンを使用する場合を例示したが、ソルビトール、マルチトール、ポリエチレングリコール等を、単独または併用して使用することができる。 For example, although the case where glycerin is used as a plasticizer was illustrated, sorbitol, maltitol, polyethylene glycol, etc. can be used alone or in combination.
Claims (6)
グルコン酸ナトリウム及びグルコン酸カリウムの何れかであるグルコン酸塩と、
低メトキシルペクチンと、
イオタカラギーナンとを含有し、
ゼラチンを含有しない
ことを特徴とするソフトカプセル皮膜。 Glutinous corn starch that has been wet-heat treated in the presence of salt;
A gluconate which is either sodium gluconate or potassium gluconate;
Low methoxyl pectin,
Contains iota carrageenan,
A soft capsule film characterized by not containing gelatin.
ことを特徴とする請求項1に記載のソフトカプセル皮膜。 The soft capsule film according to claim 1, wherein the low methoxyl pectin has an esterification degree of 26% to 27% and an amidation degree of 20% to 22%.
ことを特徴とする請求項1または請求項2に記載のソフトカプセル皮膜。 The gluconate is contained in an amount of 5.0 to 5.5 parts by weight with respect to 100 parts by weight of glutinous corn starch that has been wet-heat treated in the presence of salt. Item 3. The soft capsule film according to Item 2.
ことを特徴とする請求項1乃至請求項3の何れか一つに記載のソフトカプセル皮膜。 4 to 45 parts by weight of iota carrageenan per 100 parts by weight of glutinous corn starch that has been wet-heat treated in the presence of salt. Soft capsule film as described in 1.
ことを特徴とする請求項1乃至請求項4の何れか一つに記載のソフトカプセル皮膜。 The soft capsule film according to any one of claims 1 to 4, wherein the low methoxyl pectin having a mass ratio to iota carrageenan of 2: 1 to 1.8: 1 is contained.
ことを特徴とするソフトカプセル。 A soft capsule, wherein the soft capsule film according to any one of claims 1 to 5 is filled with a content.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014066728A JP6292938B2 (en) | 2014-03-27 | 2014-03-27 | Soft capsule film and soft capsule |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014066728A JP6292938B2 (en) | 2014-03-27 | 2014-03-27 | Soft capsule film and soft capsule |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015189684A true JP2015189684A (en) | 2015-11-02 |
JP6292938B2 JP6292938B2 (en) | 2018-03-14 |
Family
ID=54424508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014066728A Active JP6292938B2 (en) | 2014-03-27 | 2014-03-27 | Soft capsule film and soft capsule |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6292938B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016052699A1 (en) * | 2014-10-03 | 2016-04-07 | 富士カプセル株式会社 | Soft capsule coating film |
EP3556358A1 (en) * | 2018-04-18 | 2019-10-23 | Dah Feng Capsule Industry Co., Ltd. | Acid resistant capsule shell composition |
JP2021100917A (en) * | 2019-12-24 | 2021-07-08 | 中日本カプセル 株式会社 | Soft capsule film, soft capsule, and production method of soft capsule |
US11980691B2 (en) | 2018-03-15 | 2024-05-14 | R.P. Scherer Technologies, Llc | Enteric softgel capsules |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61151127A (en) * | 1984-12-25 | 1986-07-09 | Meiji Milk Prod Co Ltd | Production of soft capsule containing bifidus bacteria |
JPH0427352A (en) * | 1990-05-22 | 1992-01-30 | Fuji Capsule Kk | Enteric soft capsule for health food |
JP2001245609A (en) * | 2000-03-06 | 2001-09-11 | Suheung Capsule Co Ltd | Cellulose capsule using mixture solution of pectin with glycerol and method for producing the same |
JP2010047548A (en) * | 2008-08-25 | 2010-03-04 | Nakanihon Capsule Co Ltd | Method for producing enteric soft capsule, and enteric soft capsule |
JP2010180159A (en) * | 2009-02-05 | 2010-08-19 | Catalent Japan Kk | Film-forming composition for soft capsule |
JP2011026262A (en) * | 2009-07-28 | 2011-02-10 | Nakanihon Capsule Co Ltd | Method for manufacturing soft capsule |
JP2014015431A (en) * | 2012-07-10 | 2014-01-30 | Nakanihon Capsule Co Ltd | Soft capsule coating and soft capsule |
-
2014
- 2014-03-27 JP JP2014066728A patent/JP6292938B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61151127A (en) * | 1984-12-25 | 1986-07-09 | Meiji Milk Prod Co Ltd | Production of soft capsule containing bifidus bacteria |
JPH0427352A (en) * | 1990-05-22 | 1992-01-30 | Fuji Capsule Kk | Enteric soft capsule for health food |
JP2001245609A (en) * | 2000-03-06 | 2001-09-11 | Suheung Capsule Co Ltd | Cellulose capsule using mixture solution of pectin with glycerol and method for producing the same |
JP2010047548A (en) * | 2008-08-25 | 2010-03-04 | Nakanihon Capsule Co Ltd | Method for producing enteric soft capsule, and enteric soft capsule |
JP2010180159A (en) * | 2009-02-05 | 2010-08-19 | Catalent Japan Kk | Film-forming composition for soft capsule |
JP2011026262A (en) * | 2009-07-28 | 2011-02-10 | Nakanihon Capsule Co Ltd | Method for manufacturing soft capsule |
JP2014015431A (en) * | 2012-07-10 | 2014-01-30 | Nakanihon Capsule Co Ltd | Soft capsule coating and soft capsule |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016052699A1 (en) * | 2014-10-03 | 2016-04-07 | 富士カプセル株式会社 | Soft capsule coating film |
US11980691B2 (en) | 2018-03-15 | 2024-05-14 | R.P. Scherer Technologies, Llc | Enteric softgel capsules |
EP3556358A1 (en) * | 2018-04-18 | 2019-10-23 | Dah Feng Capsule Industry Co., Ltd. | Acid resistant capsule shell composition |
CN110384675A (en) * | 2018-04-18 | 2019-10-29 | 大丰胶囊工业股份有限公司 | Antiacid capsule shell composition |
US10813887B2 (en) | 2018-04-18 | 2020-10-27 | Dah Feng Capsule Industry Co., Ltd | Acid resistant capsule shell composition |
JP2021100917A (en) * | 2019-12-24 | 2021-07-08 | 中日本カプセル 株式会社 | Soft capsule film, soft capsule, and production method of soft capsule |
JP7411990B2 (en) | 2019-12-24 | 2024-01-12 | 中日本カプセル 株式会社 | Soft capsule film, soft capsule, and method for producing soft capsule |
Also Published As
Publication number | Publication date |
---|---|
JP6292938B2 (en) | 2018-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3205338B1 (en) | Method of manufacturing enteric soft capsule | |
JP6292938B2 (en) | Soft capsule film and soft capsule | |
KR101917334B1 (en) | Method of manufacturing enteric seamless soft capsule | |
US10493036B2 (en) | Enteric capsule | |
JP2010047548A (en) | Method for producing enteric soft capsule, and enteric soft capsule | |
JP2015007008A (en) | Shell formation composition for soft capsules, and soft capsule | |
JP7411990B2 (en) | Soft capsule film, soft capsule, and method for producing soft capsule | |
JP2005139152A (en) | Capsule coating film composition and gelatin capsule | |
JP6267066B2 (en) | Controlled release soft capsule | |
WO2023036581A1 (en) | A film-forming composition comprising pectin | |
NZ730337B2 (en) | Method of manufacturing enteric seamless soft capsule | |
CN118284404A (en) | Composition comprising gelatin, gelatin film and capsule | |
JP2020203852A (en) | pH-RESPONSIVE ELUENTS, pH-RESPONSIVE ELUENT-COATED GRANULES, FOODS, AND PHARMACEUTICALS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170324 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180117 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180213 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6292938 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |